Pharma R&D

In December 2015 we launched our sixth annual report on ‘Measuring the return from pharmaceutical innovation’.  Our research highlights the difficulties that the largest pharmaceutical companies face in delivering sustainable returns on their late stage R&D pipelines. Indeed, while the cost to develop an asset has increased by a third since we started our analysis six years ago, forecast average peak sales has declined by half. Additionally, our measure of forecast R&D return on investment (RoI) has also shown a significant downward trend, with the average across the 12 companies declining from over ten per cent in 2010 to just over four per cent in 2015.

But it’s not all doom and gloom. These averages hide a range of individual company results which vary significantly. Specifically, for the period 2013-15, three-year average returns ranged from -1.4 per cent to 10.2 per cent across the 12 companies. This year we also analysed four mid- to large-cap companies who, over the same time period, delivered average returns of 17 per cent. This highlights not only the different journeys that R&D companies are taking but also that they are using different operating models to deliver their pipelines. 

A combination of factors continue to create difficult market conditions for pharmaceutical R&D:

  • the global economic crisis in 2008 and resulting healthcare austerity measures
  • increasing market entry hurdles put in place by pricing and reimbursement bodies
  • the challenge of identifying commercial opportunities which will deliver sustainable returns
  • emergence of developing economies exhibiting different medical needs from traditional markets.

One of the challenges driving R&D transformation is the realisation by all stakeholders that healthcare budgets struggle to afford the myriad of expensive new medicines coming to market. New drugs are increasingly focussed on smaller patient populations, each with discrete clinical needs that require specific interventions – limiting the available patient pool for new drug launches and, ultimately, the levels of return that can be derived from a new drug development.

The industry is arguably a victim of its own success. Diseases that have previously exerted a huge toll on society: diabetes, asthma, and increasingly many cancers, are generally well controlled. This is due to the plethora of effective drugs that are now available to physicians which have delivered improvements such as reduced mortality and morbidity. There is a growing body of evidence quantifying the impact of medical innovations on life expectancy:

  • new chemical entity launches (drugs with a new active ingredient which has not previously been available) have been credited with increasing life expectancy by 0.8 years, almost three weeks, between 1986-2000 across 52 countries
  • the reduction in deaths from heart disease in the US by almost 70 per cent, between 1950-2010 is attributed to the introduction of new chemical entities targeting heart disease between 1950-1980.

The industry is now having to focus more of its efforts on addressing the most complex, difficult-to-treat, niche patient populations and/or diseases which are poorly understood – both carrying a higher risk of drug failure, potentially higher development costs and higher market access hurdles. In addition, these also comprise areas of unmet clinical need that society desperately needs new medicines to address. Alzheimer’s is one such condition where, between 2000 and 2012, 244 drugs were undergoing clinical trials for Alzheimer’s yet only one received marketing approval.  This level of failure is simply unsustainable for an industry that needs sufficient revenue to be generated through product sales for investors to reinvest into developing the drugs of the future. It is also sobering for the many individuals around the globe currently caring for sufferers, or entering the latter stages of their life and likely to suffer from the condition in the near future, that no effective treatments exist or are even in late stages of development.

So what is industry doing to address these challenges? There are a number of strategies that we see being followed, each with its own merits, including:

  • Focus - some companies are divesting or swapping non-core business units and therapy areas to allow them to deliver a more focussed portfolio of assets. Our analysis indicates that this should drive better levels of success and returns – those companies with more stable portfolios tend to deliver more, higher value assets. R&D teams can develop a better, detailed understanding of a disease or pathway over a period of time, as well as learning from projects which have failed, which is more likely to deliver commercial success.
  • Collaboration – between peers, other large pharmaceutical companies, and with academia and healthcare providers, is providing additional opportunities to deliver exciting innovations to patients.
  • Regulatory engagement - open dialogue between regulators and the pharmaceutical industry is increasing, aimed at expediting the launch of new drugs so that patients can realise the benefits of medical innovations faster.
  • Streamlining R&D operations – companies are seeking to arrest burgeoning drug development costs by targeting unproductive infrastructure, seeking to become more nimble and agile like their smaller counterparts, and tapping into emerging technologies such as remote clinical trial monitoring to reduce costs.

There are a number of diseases currently posing a significant threat to society: the Zika virus, multi-drug resistant bacterial infections and dementia to name just a few. Without a healthy pharmaceutical industry we will struggle to address these threats and continue to enjoy healthy, productive lives.  Without sustainable returns, life sciences companies will not have the capacity to invest in developing and launching the medicines of the future. All stakeholders within the healthcare ecosystem are starting to align their thinking and realise that they need to work together to sustain the stream of innovative medicines that have fundamentally changed our lives. Despite the recent and on-going challenges, there are signs that pharmaceutical R&D remains relatively healthy.

Karen Young

Karen Young
Senior Research Manager, Centre for Health Solutions
LinkedIn

____________________________________________________________________________

i The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001, Frank R. Lichtenberg, June 2003. NBER Working Paper No. 9754. See also: http://www.nber.org/papers/w9754.pdf

ii The Value of Medical Innovation: Power of Medical Innovation. See also: http://valueofinnovation.org/power-of-innovation/#ref2

iii Alzheimer’s disease drug-development pipeline: few candidates, frequent failures, Jeffrey L Cummings, Travis Morstorf and Kate Zhong, 3 July 2014, Alzheimer's Research & Therapy 2014 6:37. See also: http://alzres.biomedcentral.com/articles/10.1186/alzrt269#B13

Comments

  • I think we're moving towards greater accuracy when it comes to using the correct drugs, and hopefully even using less drugs and just more natural vitamins and supplements based on specific testing and results where we can figure out a patient's specific biochemical makeup.

    Posted by: Peter Dove on 18/08/2016

  • Good quality research and development (R&D) is crucial to the long-term success of the pharmaceutical industry and more generally, the wider life-sciences sector, but acquiring adequate funding is often viewed as a challenge, particularly at the feasibility or concept stage of R&D.

    Posted by: Ellen Gomez on 02/12/2016

  • Yes, I agree that the different companies are starting to see the benefit of collaboration. This will undoubtedly lead to more and faster progress in this field.

    Posted by: T Cain on 23/05/2017

  • This information is very educative

    Posted by: Hawi Moore on 26/05/2017

  • nice information.

    Posted by: maryjane on 29/05/2017

  • i like it,it is very informative

    Posted by: Stephanie Ras on 30/05/2017

  • Yes, hopefully this will streamline new medications. Many of us with chronic conditions are losing hope.

    Posted by: The Waffle Chef on 02/06/2017

  • Useful information, keep up

    Posted by: Lisa Martinn on 07/06/2017

  • Thanks for sharing this informative post.

    Posted by: Peninnah on 03/07/2017

  • Yes, looking forward to streamlining solutions!

    Posted by: Pedro on 05/10/2017

  • Thanks for sharing this informative post.

    Posted by: Pedro on 06/02/2018

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.